Healthcare provider profile · identity verified

Terry Short, MD

Internal Medicine · CHARLOTTE, NC · NPI 1114935715

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	755	254
Amlodipine Besylate	Amlodipine Besylate	543	178
Levothyroxine Sodium	Levothyroxine Sodium	370	120
Losartan Potassium	Losartan Potassium	352	112
Omeprazole	Omeprazole	350	118
Lisinopril	Lisinopril	272	94
Metformin Hcl	Metformin Hcl	257	85
Hydrochlorothiazide	Hydrochlorothiazide	228	69
Simvastatin	Simvastatin	223	67
Metoprolol Succinate	Metoprolol Succinate	166	59
Tamsulosin Hcl	Tamsulosin Hcl	161	55
Pantoprazole Sodium	Pantoprazole Sodium	156	58
Rosuvastatin Calcium	Rosuvastatin Calcium	140	51
Metformin Hcl Er	Metformin Hcl	132	35
Carvedilol	Carvedilol	130	48
Gabapentin	Gabapentin	122	37
Meloxicam	Meloxicam	121	35
Eliquis	Apixaban	106	28
Fluticasone Propionate	Fluticasone Propionate	102	32
Montelukast Sodium	Montelukast Sodium	99	38
Pravastatin Sodium	Pravastatin Sodium	97	31
Famotidine	Famotidine	95	29
Alendronate Sodium	Alendronate Sodium	90	22
Trazodone Hcl	Trazodone Hcl	90	31
Albuterol Sulfate Hfa	Albuterol Sulfate	87	28
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	86	24
Allopurinol	Allopurinol	85	30
Sertraline Hcl	Sertraline Hcl	85	30
Metoprolol Tartrate	Metoprolol Tartrate	84	29
Alprazolam	Alprazolam	83	16
Escitalopram Oxalate	Escitalopram Oxalate	79	25
Zolpidem Tartrate	Zolpidem Tartrate	78	21
Glimepiride	Glimepiride	77	27
Furosemide	Furosemide	75	29
Clopidogrel	Clopidogrel Bisulfate	69	20
Synthroid	Levothyroxine Sodium	69	21
Citalopram Hbr	Citalopram Hydrobromide	62	22
Xarelto	Rivaroxaban	58	13
Atenolol	Atenolol	56	21
Duloxetine Hcl	Duloxetine Hcl	53	16
Potassium Chloride	Potassium Chloride	53	27
Diclofenac Sodium	Diclofenac Sodium	51	20
Finasteride	Finasteride	51	17
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	49	17
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	48	15
Benazepril Hcl	Benazepril Hcl	47	13
Tramadol Hcl	Tramadol Hcl	47	12
Ezetimibe	Ezetimibe	45	15
Clonazepam	Clonazepam	43	suppressed
Januvia	Sitagliptin Phosphate	42	12
Olmesartan Medoxomil	Olmesartan Medoxomil	39	15
Prednisone	Prednisone	38	30
Fluoxetine Hcl	Fluoxetine Hcl	34	14
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	34	suppressed
Lorazepam	Lorazepam	33	11
Glipizide Er	Glipizide	32	13
Jardiance	Empagliflozin	32	suppressed
Mirtazapine	Mirtazapine	31	suppressed
Tizanidine Hcl	Tizanidine Hcl	31	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	30	suppressed
Paroxetine Hcl	Paroxetine Hcl	30	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	29	suppressed
Valacyclovir	Valacyclovir Hcl	29	suppressed
Donepezil Hcl	Donepezil Hcl	28	suppressed
Irbesartan	Irbesartan	28	suppressed
Telmisartan	Telmisartan	28	suppressed
Lovastatin	Lovastatin	27	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	26	suppressed
Colchicine	Colchicine	25	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	25	suppressed
Chlorthalidone	Chlorthalidone	24	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	24	suppressed
Spironolactone	Spironolactone	24	suppressed
Topiramate	Topiramate	24	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	24	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	23	suppressed
Ropinirole Hcl	Ropinirole Hcl	22	suppressed
Torsemide	Torsemide	21	suppressed
Warfarin Sodium	Warfarin Sodium	21	suppressed
Clobetasol Propionate	Clobetasol Propionate	20	suppressed
Diazepam	Diazepam	20	suppressed
Dutasteride	Dutasteride	20	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	20	suppressed
Nifedipine Er	Nifedipine	20	suppressed
Naproxen	Naproxen	19	suppressed
Temazepam	Temazepam	19	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	18	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	18	suppressed
Buspirone Hcl	Buspirone Hcl	17	11
Hydralazine Hcl	Hydralazine Hcl	17	suppressed
Levetiracetam	Levetiracetam	17	suppressed
Bupropion Xl	Bupropion Hcl	16	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	16	suppressed
Terazosin Hcl	Terazosin Hcl	16	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Azithromycin	Azithromycin	14	13
Entresto	Sacubitril/Valsartan	14	suppressed
Fenofibrate	Fenofibrate	14	suppressed
Glipizide	Glipizide	14	suppressed
Lansoprazole	Lansoprazole	14	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	14	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	14	suppressed
Propranolol Hcl Er	Propranolol Hcl	14	suppressed
Fenofibrate	Fenofibrate,micronized	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	12	suppressed
Bupropion Hcl Sr	Bupropion Hcl	12	suppressed
Ibandronate Sodium	Ibandronate Sodium	12	suppressed
Mometasone Furoate	Mometasone Furoate	12	suppressed
Nebivolol Hcl	Nebivolol Hcl	12	suppressed
Trulicity	Dulaglutide	12	suppressed
Ventolin Hfa	Albuterol Sulfate	12	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	11	suppressed
Levemir Flexpen	Insulin Detemir	11	suppressed
Ramipril	Ramipril	11	suppressed
Sildenafil Citrate	Sildenafil Citrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error